Esperion Therapeutics | ESPR - Cost Of Sales

Stock Price
2.78
Daily Change
0.16 5.92%
Monthly
-17.41%
Yearly
70.25%
Q1 Forecast
2.47

Esperion Therapeutics reported $27.85M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 26.05M 1.41M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Cipla INR 29.1B 1.16B Dec/2025
CSL USD 3.87B 2.08B Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Geron USD 1.31M 263K Dec/2025
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 452M 245M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024